Individual and ethnic differences in CYP2C19 activity in Chinese populations

Acta Pharmacologica Sinica

Volumn 21, Issue 3, 2000, Pages 193-199

  Shu, Yan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Alleles; Cytochrome P 450 CYP2C19; Mephenytoin; Mongoloid race; Pharmacokinetics; Polymorphism (genetics)

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CYTOCHROME P450 2C19; DIAZEPAM; IMIPRAMINE; PROPRANOLOL; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; CHINESE; DEMETHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; REVIEW;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; GENE FREQUENCY; HUMANS; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 0034063008     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20; 350-73.
2. Küpfer A, Patwardhan R, Ward S, Schenker S, Preisig R, Branch RA. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. J Pharmacol Exp Ther 1984; 230: 28-33.
3. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-96.
4. Wrighton SA, Stevens JC, Becker GW, Van den Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin hydroxylation. Arch Biochem Biophys 1993; 306: 240-5.
5. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Raucy JL, Kitareewan S, et al. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994; 33: 1743-52.
6. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin 4′-hydroxylation. Pharmacol Ther 1989; 43: 53-76.
7. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Orientals: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
8. Xie HG, Huang SL, Zhou HH. High-performance liquid chromatographic determination of urinary 4′-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. J Chromatogr Biomed Appl 1995; 668: 125-31.
9. Huang SL, Xie HG, Wang W, Xu ZH, Jiang CH, Zhou HH. Determination of S/R ratio of mephenytoin in human urine by chiral HPLC and ultraviolet detection and its comparison with gas chromatography. Acta Pharmacol Sin 1998; 19: 548-50.
10. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-11.
11. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281: 604-9.
12. Van FY, Xie HG, Huang SL, Wang W, Xu ZH, Jiang CH, et al. Genetic polymorphism of S-mephenytoin hydroxylase in a Chinese Bai population. Natl Med J Chin 1997; 77: 780-1.
13. Lou YQ, Kuang TY. Hydroxylation polymorphism of S-mephenytoin and debrisoquin in native Chinese Zhuang volunteers. The third China-Japan Joint Meeting on Pharmacology; 1993 May 11-14; Beijing, China.
14. Ruan ZR, Cheng YS, Zhou JF, Zhao Y, Pan YZ, Ding DY. Generic polymorphism of 4′-hydroxylation of S-mephenytoin in 148 Chinese of Han nationality. Acta Pharmacol Sin 1996; 17: 119-21.
15. Bertilsson L, Lou YQ, Du YL, Kuang TY, Liao XM, Wang KY, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-97.
16. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p (4′)-hydroxylation: differences between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483-7.
17. Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, Zhou HH. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis. Pharmacogenetics 1996; 6: 235-8.
18. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
19. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
20. Xie HG, Xiao ZS, Huang SL, Xu ZH, He N, Lu YQ, et al. Genotyping of S-mephenytoin hydroxylase in a Chinese population. Chin J Med Genet 1996; 13: 149-51.
21. Zhao L, Lou YQ, Fan MZ. The molecular basis of genetic variation of S-mephenytoin/omeprazole oxidative polymorphism in Chinese subjects. Chin J Clin Pharmacol 1996; 12: 13-9.
22. Zhao LH, Sun HY, Zheng NN, Li JH, Yao TW, Chen SQ. Analysis of single base mutation of cytochrome P4502C19 allele CYP2C19ml. Chin J Mod Appl Pharm 1998; 15: 36-8.
23. Zhao LH, Sun HY, Fu YF, Kong XF, Chen SQ. The detection of CYP2C19m2 mutation by allele-specific amplification. Zhejiang Can J 1998; 4: 162-3.
24. Ibeanu GC, Goldstein JA. Meyer UA, Benhamou S, Bouchardy C. Dayer P, et al. Identification of new human CYP2C19 alleles (CYP2C19 * 6 and CYP2C19 * 2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286: 1490-5.
25. Xiao ZS, Xie HG, He N, Huang SL, Xu ZH, Zhou HH. The effect of gene dose on the activity of S-mephenytoin hydroxylase. Natl Med J Chin 1996; 76: 389-90.
26. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30: 471-5.
27. Feng HJ, Huang SL, Wang W, Zhou HH, The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to ml mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998; 45: 27-9.
28. Wan J, Xia H, He N, Lu YQ, Zhou HH. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 1996; 42: 471-4.
29. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996; 42: 518-21.
30. Xie HG, Zhou HH. Gender pharmacology or pharmacogenderetics? Hunan Med J 1992; 9: 364-6.
31. Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH. Evidence for the effect of gender on activity of S-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 1997; 7: 115-9.
32. Goldstein JA, de Morais SM. Biochemistry and molecular biology of human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-99.
33. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations. Clin Pharmacol Ther 1993; 53: 608-10.
34. Xie HG. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects [ letter ]. Clin Phannaeol Ther 1997; 62: 691-2.
35. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989; 45: 72-9.
36. Xie HG, Xu ZH, Huang SL, Liu JH, Wu JX, Jiang CH, et al. No correlation between side-chain oxidation of propranolol and S-mephenytoin 4′-hydroxylase activity. Acta Phamacol Sin 1997; 18: 216-8.
37. Xu ZH, Wang W, Huang SL, He N, Shu Y, Liu ZQ, et al. Evidence for involvement of polymorphic CYP2C19 and CYP2C9 in the N-demethylation of sertraline by human liver microsomes. Br J Clin Pharmacol 2000; 48: 416-23.
38. Shu Y, Xu ZH, Xie HG, Zhu RH, Zhao JP, Zhou HH. Enzyme kinetic analysis and inhibition of amitriptyline N-demethylation in human liver microsomes in vitro. Chin J Pharmacol Toxicol 1998; 12: 260-5.
39. Wu ZL, Huang SL, Ou-Yang DS, Xu ZH, Xie HG, Zhou HH. Clomipramine N-demethylation metabolism in human liver microsomes. Acta Phamacol Sin 1998; 19: 433-6.
40. Xu ZH, Huang SL, Zhou HH. Inhibition of imipramine N-demethylation by fluvoxamine in Chinese young men. Acta Pharmacol Sin 1996; 17: 399-402.